Archive | Health Professionals

Pembrolizumab Is Effective in Unresectable Melanoma, at 4-Year Follow-Up

After 4 years of follow-up, pembrolizumab demonstrated durable antitumor activity and improved outcomes over ipilimumab in advanced melanoma, according to results from the KEYNOTE-006 trial.

Read the full story

Posted in Melanoma In The News, Health Professionals

What Surveillance Testing Should Be Done After Melanoma Diagnosis?

MedicalResearch.com: What is the background for this study? What are the main findings?

Read the full story

Posted in Melanoma In The News, Information

T-VEC Immunotherapy Shows Promising Early Activity in Melanoma

Twelve weeks of neoadjuvant exposure to talimogene laherparepvec (T-VEC) was associated with few high-grade toxicities and a promising pathological complete tumor-response (pCR) rate

Read the full story

Posted in Melanoma In The News, Clinical Trials

Encorafenib plus binimetinib prolongs OS for advanced BRAF-mutated melanoma

Combination therapy with encorafenib plus binimetinib significantly improved OS compared with vemurafenib or encorafenib alone for patients with advanced BRAF-mutated melanoma, according to phase 3 results from the COLUMBUS trial presented at ASCO Annual Meeting.

Read the full story

Posted in Melanoma In The News, Clinical Trials

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories